explore -WSS

explore

author：comprehensive 2025-08-30 11:02:39 - browse：96624

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Type 2 diabetes prevention programs work at large scale: study

explore

leisure time

WSS

Today's health inequities arise from racist U.S. history, say experts

Medicare Advantage 2025 payments will dip, Biden administration says

Republican states more likely to report Covid vaccine side effects

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

People with mental disorders often marry others with same

Drug companies' payments and gifts affect physicians' prescribing

focus

explore

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Four alarming medical procedures we’re glad history forgot

Psychedelics group wrestles with new pharma identity

Republican states more likely to report Covid vaccine side effects

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medical school prerequisites are outdated

BioMarin wins approval for gene therapy to treat hemophilia A

Type 2 diabetes prevention programs work at large scale: study

Affirmative action in medical school literally saved lives

U.K. decision on ALS drug has neurologists, advocates up in arms

Wikipedia

First transplant of an entire human eye performed

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Medicare’s new pay boost for primary care is angering specialists

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Medical school prerequisites are outdated

Four alarming medical procedures we’re glad history forgot

explore

explore

leisure time

entertainment